抗N-甲基-D-天冬氨酸受体脑炎29例回顾分析

摘要
图/表
参考文献(24)
相关文章 (6)

全文: PDF (511 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎的临床表现、磁共振（MRI）图像、脑脊液（CSF）特点及治疗转归。方法选取2011年1月~2017年3月济南军区总医院、山东大学齐鲁医院、山东省立医院、山东大学第二医院29例抗NMDAR脑炎患者的临床资料，分析病例特点，随访病情转归。结果 29例患者年龄为2~70岁，平均（27.83±13.46）岁。其中男性患者12例，2例随访发现肿瘤；女性患者17例，3例随访发现肿瘤。本研究29例患者临床症状表现为精神症状（89.7%）、癫痫发作（69.0%）、运动障碍（65.5%）、中枢性低通气（20.7%）、意识水平下降（44.8%）及自主神经功能障碍（58.6%）。CSF常规、生化检查阳性率为70.0%，96.6%患者血清抗NMDAR抗体阳性，所有患者CSF中抗NMDAR抗体阳性。82.8%出现脑电图异常，多表现为双额、颞、中央导联为主的轻度（20.7%）至中重度（62.1%）慢波。55.2%患者头颅MRI检查有异常表现，多见于额颞叶T2-Flair异常信号。所有患者均给予免疫治疗，5例患者接受利妥昔单抗、环磷酰胺或硫唑嘌呤治疗，1例患者接受血浆置换治疗，1例合并小细胞癌患者行化疗，2例合并畸胎瘤患者行手术治疗。3例患者随访死亡，26例患者预后良好（改良Rankin量表评分0~2分）占89.7%。结论 CSF抗NMDAR抗体阳性为其主要实验室检查异常项。绝大部分患者脑电图异常，并与病情严重程度相关。大多数患者早期一线免疫治疗效果良好，合并肿瘤的患者及早的手术切除及化疗可以减轻病情，改善预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钱颖1 曹秉振2

关键词 ：抗N-甲基-D-天冬氨酸受体脑炎, 临床表现, 脑脊液, 核磁共振, 治疗转归

Abstract：Objective To explore the clinical characteristics of anti-NMDAR encephalitis, including clinical manifestation, magnetic resonance imaging (MRI) findings, cerebrospinal fluid changes (CSF) and treatment outcome. Methods Clinical data of 29 cases with anti-NMDAR encephalitis from January 2011 to March 2017 were collected in four medical centers, including Ji′nan Military General Hospital, Qilu Hospital of Shandong University, Shandong Provincial Hospital, and the Second Hospital of Shandong University. The characteristics of cases were analyzed and the patients were followed up. Results The age of 29 patients was ranged from 2 to 70 years, with a mean value of (27.8±13.46). There were 12 males and 17 females. Tumors were detected in 2 males and 3 females during the follow-up periods. The clinical manifestations included psychiatric symptoms (89.7%), seizures (69.0%), dyskinesia (65.5%), hypoventilation (20.7%), recognizant levels drop (44.8%) and autonomic instability (58.6%). Positive rate of CSF routine and biochemistry tests was 70.0%, 96.6% patients with positive anti-NMDA receptor antibodies in serum, and all patients with positive anti-NMDA receptor antibodies in CSF. The EEG records were abnormal in 82.8% patients, with mild degree (20.7%) and middle and serious degree (62.1%) in generalized or frontal to temporal areas. Abnormal MRI changes were observed in 55.2% patients, in which the most common manifestations were T2-FLAIR hyper intensities in frontal and temporal lobes. All patients were treated with immunotherapy, among of whom 5 patitents received immunosuppressive agent (Rituximab, Cyclophosphamide or Azathioprine), 1 patitent received plasmapheresis, 1 patitent diagnosed with small cell carcinoma received chemotherapy, 2 patitents were diagnosed with teratoma and received surgical resection. Death occurred in 3 patitents - during the follow-up period, the remaining 26 (89.7%) cases experienced well recoveries (modified Ranking scale 0-2). Conclusion In anti-NMDAR encephalitis patients, the positive anti-NMDAR antibody in CSF is the most common laboratory findings. The abnormal electroencephalogram (EEG) records occur in most cases and correlated with the severity of anti-NMDAR encephalitis. Most patients receive a substantial recovery by early stage first-line immunosuppressive treatments. Surgical resection and chemotherapy improve prognosis for the cases with tumors.

Key words： Anti-N-methyl-D-aspartate receptor encephalitis Clinical features CSF MRI Treatment outcom

基金资助:国家自然科学基金资助项目（81671631）。

通讯作者: 曹秉振（1962.12-），男，博士，主任医师；研究方向：神经病学。

引用本文:

钱颖1 曹秉振2. 抗N-甲基-D-天冬氨酸受体脑炎29例回顾分析[J]. 中国医药导报, 2018, 15(26): 54-57,65.
QIAN Ying1 CAO Bingzhen2. Retrospective analysis of 29 cases of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. 中国医药导报, 2018, 15(26): 54-57,65.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I26/54

[1] Dalmau J，Tüzün E，Wu HY，et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma [J]. Ann Neurol，2010，61（1）：25-36.
[2] Mann A，Machado NM，Liu N，et al. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis：a case and review of the literature [J]. J Neuropsychiatry Clin Neurosci，2012，24（2）：247-254.
[3] Wang W，Li JM，Hu FY，et al. Anti-NMDA receptor encephalitis：clinical characteristics，predictors of outcome and the knowledge gap in southwest China [J]. Eur J Neurol，2016，23（3）：621-629.
[4] Graus F，Dalmau J. Paraneoplastic neurological syndromes：diagnosis and treatment [J]. Curr Opin Neurol，2007，20（6）：732.
[5] Leypoldt F，Armangue T，Dalmau J. Autoimmune encepha-lopathies [J]. Ann N Y Acad Sci，2015，1338（1）：94-114.
[6] Rypulak E，Borys M，Piwowarczyk P，et al. Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis：a case report [J]. Mol Clin Oncol，2016，5（6）：845.
[7] Sunwoo JS，Jung DC，Choi JY，et al. Successful treatment of refractory dyskinesia secondary to Anti-N-Methyl-D-Aspartate receptor encephalitis with electroconvulsive therapy [J]. Journal of Ect，2016，32（3）：1.
[8] Lee LH，Lu CJ. Long-term and strong immunotherapy to treat Anti-N-Methyl-D-Aspartate receptor encephalitis with refractory status epilepticus [J]. Acta Neurol Taiwan，2016，25（3）：99.
[9] Shinohara Y，Minematsu K，Amano T，et al. Modified rankin scale with expanded guidance scheme and interview questionnaire：interrater agreement and reproducibility of assessment [J]. Cerebrovasc Dis，2006，21（4）：271-278.
[10] Vitaliani R，Mason W，Ances B，et al. Paraneoplastic encephalitis，psychiatric symptoms，and hypoventilation in ovarian teratoma [J]. Ann Neurol，2010，58（4）：594-604.
[11] Dalmau J，Gleichman AJ，Hughes EG，et al. Anti-NMDA-receptor encephalitis：case series and analysis of the effects of antibodies [J]. Lancet Neurol，2008，7（12）：1091-1098.
[12] Florance NR，Ba RLD，Christopher Lam MD，et al. Anti-N-methyl-D-aspartate receptor （NMDAR） encephalitis in children and adolescents [J]. Ann Neurol，2009，66（1）：11-18.
[13] Granerod J，Ambrose HE，Davies NW，et al. Causes of encephalitis and differences in their clinical presentations in England：a multicentre，population-based prospective study [J]. Lancet Infect Dis，2010，10（12）：835-844.
[14] Ryan N. Anti-N-Methyl-d-Aspartate receptor-mediated encephalitis：recent advances in diagnosis and treatment in children [J]. Curr Probl Pediatr Adolesc Health Care，2016，46（2）：58-61.
[15] Mohammad SS，Jones H，Hong M，et al. Symptomatic treatment of children with anti-NMDAR encephalitis [J]. Dev Med Child Neurol，2016，58（4）：376-384.
[16] Loughan AR，Allen A，Perna R，et al. Anti-N-Methyl-D-Aspartate receptor encephalitis：a review and neuropsychological case study [J]. Clin Neuropsychol，2016， 30（1）：150-163.
[17] Dalmau J，Lancaster E，Martinez-Hernandez E，et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol，2011，10（1）：63-74.
[18] Ando Y，Shimazaki H，Shiota K，et al. Prevalence of elevated serum anti-N-methyl-D-aspartate receptor antibody titers in patients presenting exclusively with psychiatric symptoms：a comparative follow-up study [J]. BMC Psychiatry，2016，16：11.
[19] Gable MS，Gavali S，Radner A，et al. Anti-NMDA receptor encephalitis：report of ten cases and comparison with viral encephalitis [J]. Eur J Clin Microbiol Infect Dis，2009， 28（12）：1421-1429.
[20] Barry H，Hardiman O，Healy DG，et al. Anti-NMDA receptor encephalitis：an important differential diagnosis in psychosis [J]. Br J Psychiatry，2011，199（6）：508-509.
[21] Dalmau J，Lancaster E，Martinez-Hernandez E，et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol，2011，10（1）：63-74.
[22] Titulaer MJ，Mccracken L，Gabilondo I，et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis：an observational cohort study [J]. Lancet Neurol，2013，12（2）：157-165.
[23] Suppiej A，Nosadini M，Zuliani L，et al. Plasma exchange in pediatric anti-NMDAR encephalitis：A systematic review [J]. Brain Dev，2016，38（7）：613-622.
[24] 贺菲菲，叶静，董恺，等.抗N-甲基-D-天冬氨酸受体脑炎患者的临床、磁共振成像和脑脊液特征分析[J].中华神经科杂志，2014，10（47）：691-694.